Potensi Candesartan dalam Terapi COVID-19

Amelia Handoko, Gembong Satria Mahardhika, Haidar Zain


Coronavirus disease 2019 (COVID-19) akibat severe acute respiratory syndrome coronavirus 2019 (SARS-CoV-2) menyebabkan kerusakan paru dan mortalitas bagi penderitanya. Di awal pandemi COVID-19, penggunaan obat antihipertensi RAS blocker diduga berperan dalam keluaran yang kurang baik pada pasien COVID-19 dengan hipertensi karena secara teoritis akan meningkatkan ekspresi ACE2 dan memperbanyak jalan masuk virus ke dalam organ. Beberapa penelitian terkini menyatakan sebaliknya. Studi preliminary menunjukkan penurunan mortalitas dan luaran kritis pasien dengan terapi ARB. Candesartan dalam studi in-vitro dapat mengurangi badai sitokin pada COVID-19 dan berpotensi mengurangi efek destruktif lain dari infeksi SARS-CoV-2. Candesartan dapat menekan inflamasi berlebih dan mengurangi stres oksidatif, sehingga berpotensi bermanfaat dalam terapi infeksi akut SARS-CoV-2. Candesartan juga bermanfaat mengurangi komplikasi jangka panjang, bermanfaat untuk fungsi paru dan organ-organ lainnya.


Coronavirus disease 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus 2019 (SARS-CoV-2) infection causes lung damage and mortality. At early COVID-19 pandemic stage, use of RAS blocker as antihypertensive drugs was discouraged because it potentially increases the expression of ACE2, therefore increase viral entry into organs. Nevertheless, recent researches suggests otherwise. Preliminary studies has shown reduction in mortality and critical outcomes of patients with ARB therapy. Candesartan in-vitro wasable to reduce cytokine storm in COVID-19 and potentially reduce other destructive effects of SARS-CoV-2 infection by surpressing excessive inflammation and reducing oxidative stress; potentially benefits acute treatment of SARS-CoV-2 infection. Candesartan also play a role in reducing long-term complications of the disease, improving lung function as well as other organs.

Full Text:



Ghebreyesus TA. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020. WHO Director General’s speeches [Internet]. 2020.

Available from: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020

Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. Journal of Advanced Research. 2020;24:91-8. doi:10.1016/j.jare.2020.03.005

Vasileva D, Badawi A. C-reactive protein as a biomarker of severe H1N1 influenza. Inflammation Research 2019;68(1):39-46. doi:10.1007/s00011-018-1188-x

Bhat AH, Dar KB, Anees S, Zargar MA, Masood A, Sofi MA, et al. Oxidative stress, mitochondrial dysfunction and neurodegenerative diseases; A mechanistic insight. Biomedicine and Pharmacotherapy. 2015;74:101-10. doi:10.1016/j.biopha.2015.07.025

Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 2005;436(7047):112-6.doi:10.1038/nature03712

Yang G, Tan Z, Zhou L, Yang M, Peng L, Liu J, et al. Effects of angiotensin II receptor blockers and ACE (angiotensin-converting enzyme) inhibitors on virus infection, inflammatory status, and clinical outcomes in patients with COVID-19 and hypertension: A single-center retrospective study. Hypertension 2020;76(1):51-8.


Nofiartika F, Susetyowati S, Pramantara IDP, Lestari LA. Pengaruh ekstrak teh hijau (Camellia sinensis) terhadap kadar malondialdehid (MDA) plasma dan kekuatan genggam tangan lanjut usia. Jurnal Gizi Klinik Indonesia 2016;13(2):59. doi:10.22146/ijcn.22833

Nehme A, Zouein FA, Zayeri ZD, Zibara K. An update on the tissue renin angiotensin system and its role in physiology and pathology. Journal of Cardiovascular Development and Disease 2019;6(2):14. doi:10.3390/jcdd6020014

Romero CA, Orias M, Weir MR. Novel RAAS agonists and antagonists: Clinical applications and controversies. Nature Reviews Endocrinology. 2015;11(4):242-52. doi:10.1038/nrendo.2015.6

Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Development Research 2020;81(5):537-40. doi:10.1002/ddr.21656

Hülsmann S, Khabbazzadeh S, Meissner K, Quintel M. A potential role of the renin-angiotensin-system for disturbances of respiratory chemosensitivity in acute respiratory distress syndrome and severe acute respiratory syndrome. Frontiers in Physiology 2021;11:588248. doi:10.3389/fphys.2020.588248

de Abajo FJ, Rodríguez-Martín S, Lerma V, Mejia-Abril G, Aguilar M, Garcia-Luque A, et al. Use of renin–angiotensin–aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: A case-population study. The Lancet 2020;395(10238):1705-14. doi:10.1016/S0140-6736(20)31030-8

Kim J, Choi SM, Lee J, Park YS, Lee CH, Yim JJ, et al. Effect of renin-angiotensin system blockage in patients with acute respiratory distress syndrome: A retrospective case control study. The Korean Journal of Critical Care Medicine 2017;32(2):154-63.doi:10.4266/kjccm.2016.00976

Li SW, Lai CC, Ping JF, Tsai FJ, Wan L, Lin YJ, et al. Severe acute respiratory syndrome coronavirus papain-like protease suppressed alpha interferon-induced responses through downregulation of extracellular signal-regulated kinase 1-mediated signalling pathways. Journal of General Virology 2011;92(5):1127-40. doi:10.1099/vir.0.028936-0

Uhal BD, Li X, Xue A, Gao X, Abdul-Hafez A. Regulation of alveolar epithelial cell survival by the ACE-2/angiotensin 1–7/ Mas axis. American Journal of Physiology-Lung Cellular and Molecular Physiology 2011;301(3):269-74. doi:10.1152/ajplung.00222.2010

Revercomb L, Hanmandlu A, Wareing N, Akkanti B, Karmouty-Quintana H. Mechanisms of pulmonary hypertension in acute respiratory distress syndrome (ARDS). Frontiers in Molecular Biosciences 2021;7:624093. doi:10.3389/fmolb.2020.624093

Fujita M. Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth. Carcinogenesis 2004;26(2):271-9. doi:10.1093/carcin/bgh324

Bernardi S, Michelli A, Zuolo G, Candido R, Fabris B. Update on RAAS modulation for the treatment of diabetic cardiovascular disease. Journal of Diabetes Research 2016;2016:1-17. doi:10.1155/2016/8917578

Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? The Lancet Respiratory Medicine 2020;8(4):21. doi:10.1016/S2213-2600(20)30116-8

Shibata S, Arima H, Asayama K, Hoshide S, Ichihara A, Ishimitsu T, et al. Hypertension and related diseases in the era of COVID-19: A report from the Japanese Society of Hypertension Task Force on COVID-19. Hypertension Research 2020;43(10):1028-46. doi:10.1038/s41440-020-0515-0

Nejat R, Sadr AS, Freitas BT, Crabtree J, Pegan SD, Tripp RA, et al. Losartan promotes cell survival following SARS-CoV-2 infection in vitro. bioRxiv [Internet]. 2020.

Available from: https://www.biorxiv.org/content/10.1101/2020.12.27.424507v1.full. doi:10.1101/2020.12.27.424507

Duarte M, Pelorosso F, Nicolosi L, Salgado MV, Vetulli H, Aquieri A, et al. Telmisartan for treatment of Covid-19 patients: An open randomized clinical trial - A preliminary report. medRxiv [Internet]. 2020. Available from: https://www.medrxiv.org/content/10.1101/2020.08.04.20167205v2. doi:10.1101/2020.08.04.20167205

Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong JC, Turner AJ, et al. Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: Celebrating the 20th anniversary of the discovery of ACE2. Circulation Research 2020;126:1456-474. doi:10.1161/CIRCRESAHA.120.317015

Ziegler CGK, Allon SJ, Nyquist SK, Mbano IM, Miao VN, Tzouanas CN, et al. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell 2020;181(5):1016-35.e19. doi:10.1016/j.cell.2020.04.035

Monteil V, Kwon H, Prado P, Hagelkruys A, Wimmer RA, Stahl M, et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell 2020;181(4):905-13.e7. doi:10.1016/j.cell.2020.04.004

Jia H. Pulmonary angiotensin-converting enzyme 2 (ACE2) and inflammatory lung disease. Shock 2016;46(3):239-48. doi:10.1097/SHK.0000000000000633

Benigni A, Cassis P, Remuzzi G. Angiotensin II revisited: New roles in inflammation, immunology and aging. EMBO Molecular Medicine 2010;2(7):247-57. doi:10.1002/emmm.201000080

Li J, Wang X, Chen J, Zhang H, Deng A. Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China. JAMA Cardiology 2020;5(7):825-30. doi:10.1001/jamacardio.2020.1624

Guo X, Zhu Y, Hong Y. Decreased mortality of COVID-19 with renin-angiotensin-aldosterone system inhibitors therapy in patients with hypertension: A metaanalysis. Hypertension Published online 2020;76(2):13-4. doi:10.1161/HYPERTENSIONAHA.120.15572

Hagiwara S, Iwasaka H, Matumoto S, Hidaka S, Noguchi T. Effects of an angiotensin-converting enzyme inhibitor on the inflammatory response in in vivo and in vitro models*. Critical Care Medicine 2009;37(2):626-33. doi:10.1097/CCM.0b013e3181958d91

Polikandriotis JA, Rupnow HL, Elms SC, Clempus RE, Campbell DJ, Sutliff RL, et al. American Journal of Respiratory Cell and Molecular Biology. 2006;34(3):314-9. doi:10.1165/rcmb.2005-0320OC

Fedson DS. Treating the host response to emerging virus diseases: Lessons learned from sepsis, pneumonia, influenza and Ebola. Annals of Translational Medicine 2016;4(21):421. doi:10.21037/atm.2016.11.03

Zhou Y, Yang Q, Chi J, Dong B, Lv W, Shen L, et al. Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: A systematic review and meta-analysis. International Journal of Infectious Diseases 2020;99:47-56. doi:10.1016/j.ijid.2020.07.029

Abraham HMA, White CM, White WB. The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases. Drug Safety 2015;38(1):33-54. doi:10.1007/s40264-014-0239-7

Soto M, Bang SI, McCombs J, Rodgers KE. Renin angiotensin system-modifying therapies are associated with improved pulmonary health. Clinical Diabetes and Endocrinology. 2017;3(1). doi:10.1186/s40842-017-0044-1

Rodriguez-Perez AI, Sucunza D, Pedrosa MA, Garrido-Gil P, Kulisevsky J, Lanciego JL, et al. Angiotensin type 1 receptor antagonists protect against alpha-synucleininduced neuroinflammation and dopaminergic neuron death. Neurotherapeutics 2018;15(4):1063-81. doi:10.1007/s13311-018-0646-z

Elkahloun AG, Saavedra JM. Candesartan could ameliorate the COVID-19 cytokine storm. Biomedicine and Pharmacotherapy 2020;131:110653. doi:10.1016/j.biopha.2020.110653

Choe SH, Choi EY, Hyeon JY, Keum BR, Choi IS, Kim SJ. Telmisartan, an angiotensin II receptor blocker, attenuates Prevotella intermedia lipopolysaccharide-induced production of nitric oxide and interleukin-1β in murine macrophages. International Immunopharmacology 2019;75:105750. doi:10.1016/j.intimp.2019.105750

Sun X, Luan Q, Qiu S. Valsartan prevents glycerol-induced acute kidney injury in male albino rats by downregulating TLR4 and NF-κB expression. International Journal of Biological Macromolecules 2018;119:565-71. doi:10.1016/j.ijbiomac.2018.07.149

Villapol S, Saavedra JM. Neuroprotective effects of angiotensin receptor blockers. American Journal of Hypertension 2015;28(3):289-99. doi:10.1093/ajh/hpu197

Costa G, Garabito M, Jiménez-Altayó F, Onetti Y, Sabate M, Vila E, et al. Sex differences in angiotensin II responses contribute to a differential regulation of coxmediated vascular dysfunction during aging. Experimental Gerontology 2016;85:71-80. doi:10.1016/j.exger.2016.09.020

Silveira KD, Coelho FM, Vieira AT, Barroso LC, Queiroz-Junior CM, Costa VV, et al. Mechanisms of the anti-inflammatory actions of the angiotensin type1 receptor antagonist losartan in experimental models of arthritis. Peptides 2013;46:53-63. doi:10.1016/j.peptides.2013.05.012

Collado A, Marques P, Escudero P, Rius C, Domingo E, Martinez-Hervas S, et al. Functional role of endothelial CXCL16/ CXCR6-platelet–leucocyte axis in angiotensin II-associated metabolic disorders. Cardiovascular Research 2018;114(13):1764-75. doi:10.1093/cvr/cvy135

Regan DP, Coy JW, Chahal KK, Chow L, Kurihara JN, Guth AM, et al. The angiotensin receptor blocker losartan suppresses growth of pulmonary metastases via AT1Rindependent inhibition of CCR2 signaling and monocyte recruitment. The Journal of Immunology 2019;202(10):3087-102. doi:10.4049/jimmunol.1800619

Hwang OK, Park JK, Lee EJ, Lee EM, Kim AY, Jeong KS. Therapeutic effect of losartan, an angiotensin II type 1 receptor antagonist, on CCl4-induced skeletal muscle injury. International Journal of Molecular Sciences 2016;17(2):227. doi:10.3390/ijms17020227

Gannon WD, Anderson MR, Podolanczuk AJ, Kawut SM, Michos ED, Cottin V, et al. Angiotensin receptor blockers and subclinical interstitial lung disease: The MESA study. Annals of the American Thoracic Society 2019;16(11):1451-3. doi:10.1513/AnnalsATS.201903-198RL

Kint J, Dickhout A, Kutter J, Maier HJ, Britton P, Koumans J, et al. Infectious bronchitis coronavirus inhibits STAT1 signaling and requires accessory proteins for resistance to type I interferon activity. Journal of Virology 2015;89(23):12047-57. doi:10.1128/jvi.01057-15

Xiong Y, Liu Y, Cao L, Wang D, Guo M, Jiang A, et al. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerging Microbes and Infections 2020;9(1):761-70. doi:10.1080/22221751.2020.1747363

Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Moller R, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 2020;181(5):1036-45.e9. doi:10.1016/j.cell.2020.04.026

Peters MC, Sajuthi S, Deford P, Christenson S, Rios CL, Montgomery MT, et al. COVID-19-related genes in sputum cells in asthma: Relationship to demographic features and corticosteroids. American Journal of Respiratory and Critical Care Medicine 2020;202(1):83-90. doi:10.1164/rccm.202003-0821OC

Violi F, Pastori D, Pignatelli P, Cangemi R. SARS-CoV-2 and myocardial injury: A role for Nox2? Internal and Emergency Medicine 2020;15(5):755-8. doi:10.1007/s11739-020-02348-6

Abouhashem AS, Singh K, Azzazy HME, Sen CK. Is low alveolar type II cell SOD3 in the lungs of elderly linked to the observed severity of COVID-19? Antioxidants and Redox Signaling 2020;33(2):59-65. doi:10.1089/ars.2020.8111

Piantadosi CA, Withers CM, Bartz RR, MacGarvey NC, Fu P, Sweeney TE, et al. Heme oxygenase-1 couples activation of mitochondrial biogenesis to anti-inflammatory cytokine expression. Journal of Biological Chemistry 2011;286(18):16374-85. doi:10.1074/jbc.M110.207738


  • There are currently no refbacks.